NEKTAR THERAPEUTICS (NKTR) stock: insider trades, news & valuation
Heavy sellingShare price and insider trades
NEKTAR THERAPEUTICS insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 3 sold $2.4M of NKTR stock on the open market.
Get emailed when insiders cluster-buy stocks like NKTR
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
NKTR insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $43K | 2 |
| Q2 2026 | — | 0 | $2.0M | 8 |
| Q1 2026 | — | 0 | $182K | 3 |
| Q4 2025 | — | 0 | $217K | 3 |
Valuation, profit and volume
Summary
Over the past 12 months, 0 NEKTAR THERAPEUTICS insiders reported open-market purchases totaling $0, while 3 insiders reported sales totaling $2.4M. 7 of 16 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Aug 20SEC | Howard W RobinCEO, President | Sell | 41854,627 held (−1%) | $71.98 | $30K | -42.8% | — |
| Aug 20SEC | Jonathan ZalevskyChief R&D Officer | Sell | 1869,570 held (−2%) | $71.98 | $13K | -42.8% | — |
| Jul 2SEC | Jonathan ZalevskyChief R&D Officer | Sell Plan | 5,6819,756 held (−37%) | $70.00 | $398K | -41.2% | — |
| Jun 18SEC | Howard W RobinCEO, President | Sell Plan | 5,50059,545 held (−8%) | $60.81 | $334K | -32.3% | — |
| Jun 18SEC | Howard W RobinCEO, President | Sell Plan | 5,30369,742 held (−7%) | $59.97 | $318K | -31.3% | — |
| Jun 18SEC | Howard W RobinCEO, President | Sell Plan | 4,69765,045 held (−7%) | $60.71 | $285K | -32.2% | — |
| Jun 18SEC | Howard W RobinCEO, President | Sell Plan | 4,50055,045 held (−8%) | $61.65 | $277K | -33.2% | — |
| Jun 17SEC | Jonathan ZalevskyChief R&D Officer | Sell Plan | 5,53815,437 held (−26%) | $60.71 | $336K | -32.2% | — |
| May 21SEC | Howard W RobinCEO, President | Sell | 44475,045 held (−1%) | $65.51 | $29K | -37.2% | — |
| May 21SEC | Jonathan ZalevskyChief R&D Officer | Sell | 19920,975 held (−1%) | $65.51 | $13K | -37.2% | — |
| Feb 20SEC | Howard W RobinCEO, President | Sell | 42375,489 held (−1%) | $73.00 | $31K | -43.6% | — |
| Feb 20SEC | Jonathan ZalevskyChief R&D Officer | Sell | 18021,174 held (−1%) | $73.00 | $13K | -43.6% | — |
| Jan 22SEC | Jonathan ZalevskyChief R&D Officer | Sell Plan | 3,86721,354 held (−15%) | $35.67 | $138K | +15.4% | — |
| Nov 25SEC | Howard W RobinCEO, President | Sell | 2,20754,245 held (−4%) | $54.28 | $120K | -24.2% | — |
| Nov 25SEC | Jonathan ZalevskyChief R&D Officer | Sell | 1,15718,971 held (−6%) | $54.28 | $63K | -24.2% | — |
| Nov 25SEC | Mark Andrew WilsonGeneral Counsel | Sell | 63021,585 held (−3%) | $54.28 | $34K | -24.2% | — |
Insiders at NEKTAR THERAPEUTICS
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Howard W RobinCEO, President | — | $1.4M | Aug 20, 2026 | — |
| Jonathan ZalevskyChief R&D Officer | — | $974K | Aug 20, 2026 | — |
| Mark Andrew WilsonGeneral Counsel | — | $34K | Nov 25, 2025 | — |
NKTR stock: common questions
Are NEKTAR THERAPEUTICS insiders buying NKTR stock?
In the past 12 months, 0 insiders reported open-market purchases of NKTR worth $0.
Are NEKTAR THERAPEUTICS insiders selling NKTR stock?
3 insiders reported sales worth $2.4M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is NKTR's 52-week range?
Over the past year NKTR has traded between $35.12 and $100.35. It last closed at $41.17 on Oct 9, 2026.